ArticleCurrent therapeutic research, clinical and experimental2025
Evaluation of Adverse Effects and Tolerability of Dietary Ginger Supplementation in Patients With Functional Dyspepsia.
Article in Current therapeutic research, clinical and experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06313814 (The Effect of Ginger on Functional Dyspepsia Symptoms and Body Fat Content Among Patients With Functional Dyspepsia), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Ginger on Functional Dyspepsia Symptoms and Body Fat Content Among Patients With Functional Dyspepsia
Who cites it
3 citing papers in PubMed.
- Ginger Bioactives as Multi-Target Therapeutics: Mechanisms, Delivery Innovation, and Human Health Impact.Nutrients · 2026Review
- Oral ginger-derived extracellular vesicles ameliorate arthritis via anti-inflammatory actions of microRNA-149 and 6-gingerol.Molecular therapy. Nucleic acids · 2026Article
- Multidirectional Effects of Acerola and Ginger Extracts on the Quality of Dry-Cured Ham.Foods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Functional dyspepsia (FD) is a prevalent upper gastrointestinal disorder characterized by chronic or recurrent symptoms, including epigastric pain, bloating, and nausea. Ginger ( Objective: To evaluate the safety, tolerability, and adverse effects of ginger supplementation in patients with FD. Methods: This open-label clinical trial was conducted at the Internal Medicine Outpatient Department, University of Debrecen. This study was conducted in full compliance with the ethical principles outlined in the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of the University of Debrecen (registry reference number: DE RKEB/IKEB 5622-2020). All participants provided written informed consent prior to their inclusion in the study. Fifty patients with FD were initially enrolled, and 47 participants completed the study. Ginger supplementation was administered at a dose of 1080 mg/d in divided doses over 8 weeks. Adverse effects were assessed weekly through clinical evaluations and self-reports, and tolerability was rated by participants at the end of the trial. Results: The study included 47 patients with FD who completed the trial, with a mean (SD) age of 51.49 (14.64) years. Of the participants, 78.7% were females. Ginger supplementation was well tolerated, with mild and transient adverse effects reported, including bloating (14.9%), heartburn (12.8%), and diarrhea (10.6%). None of these adverse events necessitated discontinuation of the treatment. Tolerability was rated as good or excellent by 87.2% of participants, and no severe adverse events were observed. Conclusions: Preliminary findings suggest ginger is well tolerated and may be a viable complementary dietary therapy, though further research is needed. ClinicalTrials.gov identifier: NCT06313814.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.